Skip to main content
Erschienen in: Annals of Hematology 4/2013

01.04.2013 | Original Article

High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia

verfasst von: Anna Hecht, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Büchner, Karsten Spiekermann, Cristina Sauerland, Eva Lengfelder, Wolf-Karsten Hofmann, Florian Nolte

Erschienen in: Annals of Hematology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

In acute promyelocytic leukemia (APL), relapse occurs in about 15 % of cases and is a major cause for death. Molecular markers identifying patients at high risk for relapse are not well established. High expression of the transcription factor Ets-related gene (ERG) is associated with inferior overall survival (OS) and disease-free survival in different types of hematologic malignancies. There are no data available about the impact of ERG expression in APL. ERG expression levels were analyzed in bone marrow samples of 86 APL patients at initial diagnosis. High ERG expression was significantly associated with an inferior OS in patients who had reached first complete remission. It was also significantly correlated with inferior relapse-free survival (RFS) and time to relapse (i.e., relapse-free interval, RFI). In multivariate analysis, high ERG expression had an independent negative impact on RFS and RFI. High ERG expression was significantly associated with inferior OS, RFS, and RFI. Moreover, in multivariate analysis, it maintained its value as an independent negative prognostic factor with regard to RFS and RFI. Therefore, ERG expression might serve as a molecular marker for risk stratification in APL and might identify patients who could benefit from intensified treatment regimens.
Literatur
1.
Zurück zum Zitat Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387PubMed Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387PubMed
2.
Zurück zum Zitat Brown D, Kogan S, Lagasse E et al (1997) A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551–2556PubMedCrossRef Brown D, Kogan S, Lagasse E et al (1997) A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551–2556PubMedCrossRef
3.
Zurück zum Zitat Ades L, Guerci A, Raffoux E et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690–1696PubMedCrossRef Ades L, Guerci A, Raffoux E et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690–1696PubMedCrossRef
4.
Zurück zum Zitat Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed
5.
Zurück zum Zitat Lengfelder E, Haferlach C, Saussele S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258PubMedCrossRef Lengfelder E, Haferlach C, Saussele S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258PubMedCrossRef
6.
Zurück zum Zitat Ichikawa H, Shimizu K, Hayashi Y, Ohki M (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54:2865–2868PubMed Ichikawa H, Shimizu K, Hayashi Y, Ohki M (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54:2865–2868PubMed
7.
Zurück zum Zitat Welford SM, Hebert SP, Deneen B et al (2001) DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276:41977–41984PubMedCrossRef Welford SM, Hebert SP, Deneen B et al (2001) DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276:41977–41984PubMedCrossRef
8.
Zurück zum Zitat Kuhnl A, Gokbuget N, Stroux A et al (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737–3744PubMedCrossRef Kuhnl A, Gokbuget N, Stroux A et al (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737–3744PubMedCrossRef
9.
Zurück zum Zitat Baldus CD, Burmeister T, Martus P et al (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24:4714–4720PubMedCrossRef Baldus CD, Burmeister T, Martus P et al (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24:4714–4720PubMedCrossRef
10.
Zurück zum Zitat Marcucci G, Maharry K, Whitman SP et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337–3343PubMedCrossRef Marcucci G, Maharry K, Whitman SP et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337–3343PubMedCrossRef
11.
Zurück zum Zitat Metzeler KH, Dufour A, Benthaus T et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031–5038PubMedCrossRef Metzeler KH, Dufour A, Benthaus T et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031–5038PubMedCrossRef
12.
Zurück zum Zitat Lengfelder E, Hanfstein B, Haferlach C et al (2012) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. doi:10.1007/s00277-012-1597-9 Lengfelder E, Hanfstein B, Haferlach C et al (2012) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. doi:10.​1007/​s00277-012-1597-9
13.
Zurück zum Zitat Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef
14.
Zurück zum Zitat Akagi T, Shih LY, Kato M et al (2009) Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113:1741–1748PubMedCrossRef Akagi T, Shih LY, Kato M et al (2009) Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113:1741–1748PubMedCrossRef
15.
Zurück zum Zitat Yaghmaie M, Mozdarani H, Alimoghaddam K et al (2012) Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol 29:1209–1216PubMedCrossRef Yaghmaie M, Mozdarani H, Alimoghaddam K et al (2012) Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol 29:1209–1216PubMedCrossRef
16.
Zurück zum Zitat de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402PubMedCrossRef de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402PubMedCrossRef
17.
Zurück zum Zitat Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134PubMedCrossRef Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134PubMedCrossRef
18.
Zurück zum Zitat Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561–4568PubMedCrossRef Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561–4568PubMedCrossRef
19.
Zurück zum Zitat Baldus CD, Martus P, Burmeister T et al (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739–3745PubMedCrossRef Baldus CD, Martus P, Burmeister T et al (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739–3745PubMedCrossRef
Metadaten
Titel
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia
verfasst von
Anna Hecht
Daniel Nowak
Verena Nowak
Benjamin Hanfstein
Andreas Faldum
Thomas Büchner
Karsten Spiekermann
Cristina Sauerland
Eva Lengfelder
Wolf-Karsten Hofmann
Florian Nolte
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 4/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1648-2

Weitere Artikel der Ausgabe 4/2013

Annals of Hematology 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.